HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

(2) GLP-1受容体作動薬 (III. 糖尿病治療薬に関する最近の話題 3. インクレチン関連薬)

Files in This Item:
JJCM_78_1139-1145.pdf7.33 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: (2) GLP-1受容体作動薬 (III. 糖尿病治療薬に関する最近の話題 3. インクレチン関連薬)
Authors: 三好, 秀明1 Browse this author →KAKEN DB
Authors(alt): Miyoshi, Hideaki1
Keywords: GLP-1 receptor agonist
cardiovascular outcome
Issue Date: 1-Jul-2020
Publisher: 日本臨牀社
Journal Title: 日本臨牀
Journal Title(alt): Japanese journal of clinical medicine
Volume: 78
Issue: 7
Start Page: 1139
End Page: 1145
Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) demonstrate hypoglycemic effects with decreasing daily glycemic variability via plasma glucose-dependent insulin secretion and glucagon suppression, and delayed gastric emptying. GLP-1RAs also reduce appetite via the central nervous system, resulting in body weight reduction. There are many other targets of GLP-1RAs reported recently such as heart, kidney, and liver. Importantly, large cardiovascular outcomes trials revealed and confirmed that GLP-1RAs reduced major adverse cardiovascular events, cardiovascular death, and chronic kidney disease progression. The priority and frequency of use of GLP-1RAs among the antihyperglycemic agents are increasing worldwide. Moreover, new kinds of GLP-1RAs, which are expected to further reduce HbA1c and body weight, will be available in the near future.
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University